(Q36385670)

13 August 2017

Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer (English)

1 reference

13 August 2017

1 reference

1 reference

19

G B Mills

1 reference

13 August 2017

3

B T Hennessy

1 reference

13 August 2017

V Abkevich

1

1 reference

13 August 2017

K M Timms

2

1 reference

13 August 2017

J Potter

4

1 reference

13 August 2017

M S Carey

5

1 reference

13 August 2017

L A Meyer

6

1 reference

13 August 2017

K Smith-McCune

7

1 reference

13 August 2017

R Broaddus

8

1 reference

13 August 2017

K H Lu

9

1 reference

13 August 2017

J Chen

10

1 reference

13 August 2017

T V Tran

11

1 reference

13 August 2017

D Williams

12

1 reference

13 August 2017

D Iliev

13

1 reference

13 August 2017

S Jammulapati

14

1 reference

13 August 2017

L M FitzGerald

15

1 reference

13 August 2017

T Krivak

16

1 reference

13 August 2017

J A DeLoia

17

1 reference

13 August 2017

A Gutin

18

1 reference

13 August 2017

J S Lanchbury

20

1 reference

13 August 2017

language of work or name

English

0 references

publication date

9 October 2012

1 reference

British Journal of Cancer

13 August 2017

1 reference

13 August 2017

107

1 reference

13 August 2017

10

1 reference

13 August 2017

1776-1782

1 reference

https://scigraph.springernature.com/pub.10.1038/bjc.2012.451

13 August 2017

0 references

cites work

Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493866

Germline mutations in RAD51D confer susceptibility to ovarian cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493866

Integrated genomic analyses of ovarian carcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493866

Defective homologous recombination in human cancers.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493866

Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493866

Iniparib plus chemotherapy in metastatic triple-negative breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493866

BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493866

Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493866

Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493866

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493866

Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493866

Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493866

Resistance to therapy caused by intragenic deletion in BRCA2

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493866

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493866

BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493866

High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493866

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493866

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493866

Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493866

Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493866

Cancer susceptibility and the functions of BRCA1 and BRCA2

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493866

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493866

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493866

“BRCAness” Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated WithBRCA1andBRCA2Mutations

21 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FBJC.2012.451

BRCA1/2 mutations and expression: Response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23047548

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Correction: Genomic profiling of breast tumours in relation to abnormalities and phenotypes

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FBJC.2012.451

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/BJC.2012.451

1 reference

13 August 2017

1 reference

13 August 2017

PubMed publication ID

23047548

1 reference